Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic DermatitisEric L. Simpson, Ashish Bansal, David M. Pariser et al.|JAMA Dermatology|2019Cited by 505
Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil CountsSurya P. Bhatt, Raolat M. Abdulai, Klaus F. Rabe et al.|New England Journal of Medicine|2023Cited by 452
Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trialAmy S. Paller, Brad Shumel, Elaine C. Siegfried et al.|Journal of the American Academy of Dermatology|2020Cited by 385
Dupilumab for COPD with Blood Eosinophil Evidence of Type 2 InflammationSurya P. Bhatt, Lacey B. Robinson, Klaus F. Rabe et al.|New England Journal of Medicine|2024Cited by 240